Donepezil, Galantamine, Rivastigmine and Memantine for Alzheimer’s (review of R111)
Award Number
09/87/01Award Type
NICE-TARProgramme
Technology Assessment ReviewsStatus / Stage
CompletedDates
12 January 2010 -25 November 2010
Duration (calculated)
00 years 10 monthsFunder(s)
NIHRFunding Amount
£0.00Funder/Grant study page
NIHRContracted Centre
University of ExeterPrincipal Investigator
Dr Mary BondWHO Catergories
Economic Impact of DementiaMethodologies and approaches for risk reduction research
Disease Type
Alzheimer's Disease (AD)CPEC Review Info
| Reference ID | 163 |
|---|---|
| Researcher | Reside Team |
| Published | 12/06/2023 |
Data
| Award Number | 09/87/01 |
|---|---|
| Status / Stage | Completed |
| Start Date | 20100112 |
| End Date | 20101125 |
| Duration (calculated) | 00 years 10 months |
| Funder/Grant study page | NIHR |
| Contracted Centre | University of Exeter |
| Funding Amount | £0.00 |
Abstract
Management of Alzheimer’s disease involves treatment of cognitive, behavioural and psychological symptoms. Non-pharmacological treatment is social support and increasing assistance with day-to-day activities. These include: information and education, carer support groups, community dementia teams; home nursing and personal care, community services such as meals-on-wheels, befriending services, day centres, respite care and care homes. The HTA Programme commissioned this tehcnology assessment report on behalf of the National Institute for Health and Clinical Excellence.
Plain English Summary
This project will review and update the evidence presented to the National Institute of Health and Clinical Excellence in 2004 of how good a number of drugs (donepezil, galantamine, rivastigmine and memantine) are for treating Alzheimer’s disease. The assessment will also assess whether the reviewed drugs are likely to be considered good value for money for the NHS.